The relative fractions of tumor-reactive host T cells were first analyzed in lymph nodes and spleens 9 days after treating B16-F10 tumor-bearing mice with one of the following: (1) no treatment controls (NT), (2) T cell only depots (TcellOnly_Depot), (3) SIVET with antigen-free FLT3L vaccine (SIVET_ FLT3L), (4) SIVET with antigen-free GMCSF vaccine (SIVET_ GMCSF), (5) antigen-free GM-CSF vaccine-only depot (Vax_GMCSF) and (6) antigen-free FLT3L vaccine-only depot (Vax_ FLT3L) (Fig. 3a). This evidence concerns the gene FLT3LG and neoplasm.